1-4 of 4
Lara Mussolin, PhD
Close
Sort by
Journal Articles

Genetic Activation and Therapeutic Targeting of PIM1 in T-Cell Acute Lymphoblastic Leukemia/Lymphoma

Renate De Smedt, MSc, Sofie Peirs, PhD, Julie Morscio, PhD, Juliette Roels, MSc, Steven Goossens, PhD, Aurore Touzart, MD, Anne Uyttebroeck, Nadine Van Roy, PhD, Tim Lammens, PhD, Lara Mussolin, PhD, Elizabeth Macyntire, MD PhD, Peter Vandenberghe, MD PhD, Pieter Van Vlierberghe, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1445.
https://doi.org/10.1182/blood.V130.Suppl_1.1445.1445
Published: 2017
Journal Articles

Elevated Level Expression of MiR-223 Is Associated with Worse Prognosis in Childhood T-Cell Lymphoblastic Lymphoma

Lara Mussolin, PhD, Elena Pomari, PhD, Marta Pillon, MD, Federica Lovisa, PhD, Elisa Carraro, PhD, Paolo Bonvini, PhD, Emanuele SG d'Amore, MD, Giuseppe Basso, MD
Journal: Blood
Blood (2016) 128 (22): 1098.
https://doi.org/10.1182/blood.V128.22.1098.1098
Published: 2016
Journal Articles

High Response Rates To Crizotinib In Advanced, Chemoresistant ALK+ Lymphoma Patients

Sara Redaelli, PhD, Francesca Farina, MD, Alessandra Stasia, MD, Monica Ceccon, PhD, Luca Mologni, PhD, Cristina Messa, MD, Luca Guerra, MD, Giovanni Giudici, MS, Elena Sala, MS, Lara Mussolin, PhD, Dries Deeren, MD, Michael H. King, MD, Michael Steurer, MD, Rainer Ordemann, MD, Amos Cohen, MD, Matthias Grube, MD, Lea Bernard, MD, Gianpaolo Chiriano, PhD, Rocco Piazza, MD, PhD, Carlo Gambacorti-Passerini, MD
Journal: Blood
Blood (2013) 122 (21): 368.
https://doi.org/10.1182/blood.V122.21.368.368
Published: 2013
Journal Articles

Early Assessment of Minimal Residual Disease (MRD) by Qualitative PCR for NPM-ALK Identifies Patients At Very High Risk of Relapse in Anaplastic Large Cell Lymphoma

Christine Damm-Welk, PhD, Lara Mussolin, PhD, Marta Pillon, MD, Martin Zimmermann, PhD, Alfred Reiter, MD, Wilhelm Woessmann, MD, Angelo Rosolen, MD
Journal: Blood
Blood (2011) 118 (21): 1565.
https://doi.org/10.1182/blood.V118.21.1565.1565
Published: 2011